Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Lilly's Amylin/Tirzepatide Combo Shows Promising Weight Loss Results in Phase I Trial

Eli Lilly has reported impressive early-stage results for its combination therapy of amylin analog eloralintide and GLP-1 receptor agonist tirzepatide in overweight or obese patients. The Phase I trial data, set to be presented at the upcoming American Diabetes Association Conference, demonstrate significant weight loss and a favorable tolerability profile.

NoahAI News6/17/2025

Regeneron Loses Bid for 23andMe to Former CEO's Nonprofit

In a surprising turn of events, Regeneron Pharmaceuticals has lost its bid to acquire the genetic testing company 23andMe to a nonprofit organization led by the company's former CEO, Anne Wojcicki. This development marks a significant shift in the ongoing saga of 23andMe's financial struggles and raises important questions about the future of genetic data privacy.

NoahAI News6/17/2025

Supernus Pharmaceuticals to Acquire Sage Therapeutics in $795M Deal

Supernus Pharmaceuticals has agreed to acquire Sage Therapeutics for up to $795 million, marking a significant development in the central nervous system (CNS) therapeutics landscape. The deal, announced on Monday, comes as a resolution to Sage's recent strategic challenges and outbids a previous unsolicited offer from Biogen.

NoahAI News6/17/2025

Harvard Researcher Secures $39M from Turkish Investment Group for Obesity Research Amid U.S. Funding Cuts

In a significant development for obesity and metabolic disease research, Harvard University researcher Gökhan Hotamışlıgil, M.D., Ph.D., has secured approximately $39 million in funding from İş Private Equity, a subsidiary of Turkey's İşbank Group. This substantial investment comes at a crucial time as U.S. federal funding for scientific research faces extensive cuts under the Trump administration.

NoahAI News6/17/2025

J&J's Dual-Targeting CAR-T Therapy Shows Promising Results in Lymphoma Study

Johnson & Johnson's investigational CAR-T therapy, JNJ-4496, has demonstrated impressive efficacy in a Phase Ib trial for large B cell lymphoma, potentially challenging the current standard of care. The study results, presented at the 2025 European Hematology Association congress, reveal high response rates and a favorable safety profile, positioning the therapy as a strong competitor in the CAR-T space.

NoahAI News6/17/2025

Supernus Acquires Sage Therapeutics for $561M, Betting on Postpartum Depression Drug Zurzuvae

In a significant industry development, Supernus Pharmaceuticals has agreed to acquire Sage Therapeutics for $561 million upfront, with potential additional payouts that could bring the total deal value to $795 million. This acquisition marks a pivotal moment for both companies and highlights the growing focus on treatments for postpartum depression (PPD) in the pharmaceutical industry.

NoahAI News6/17/2025

Sarepta's DMD Gene Therapy Elevidys Faces Setback After Second Patient Death

Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy (DMD), Elevidys, has encountered a significant setback following the death of a second patient due to acute liver failure. The incident has prompted the company to suspend treatment for certain patient groups and reevaluate its safety protocols, sending shockwaves through the gene therapy landscape.

NoahAI News6/17/2025

Amazon Restructures Healthcare Business, Aiming to Streamline Operations and Spur Growth

Amazon has announced a significant restructuring of its healthcare business, Amazon Health Services (AHS), in a move aimed at simplifying operations and accelerating innovation. The reorganization, completed in May, comes as the e-commerce giant continues to expand its footprint in the healthcare sector despite mixed results from previous initiatives.

NoahAI News6/17/2025

FDA Delays Decision on Kalvista's Hereditary Angioedema Drug, Citing Resource Constraints

The U.S. Food and Drug Administration (FDA) has announced it will miss the approval deadline for Kalvista Therapeutics' experimental drug sebetralstat, developed for the treatment of hereditary angioedema. The delay, attributed to "resource constraints" at the agency, marks a significant development in the pharmaceutical industry and raises questions about the FDA's capacity to meet review timelines.

NoahAI News6/17/2025

US Biotechs Face Shifting Landscape Amid Rising Costs and Global Competition

In a rapidly evolving pharmaceutical landscape, US biotech companies are grappling with significant challenges that are reshaping their strategies and operations. Rising costs, regulatory uncertainties, and increasing global competition, particularly from China, are forcing these firms to adapt their approaches to drug development and market positioning.

NoahAI News6/17/2025

Intermountain Health Invests in AI-Powered Chart Review Technology

Intermountain Health, a major healthcare system based in Utah, has announced a strategic investment in Layer Health, a company specializing in artificial intelligence (AI) for clinical data abstraction. This partnership aims to revolutionize quality reporting and clinical registry submissions across Intermountain's network, focusing initially on stroke, surgery, and cardiovascular disease.

NoahAI News6/17/2025

Biologics Manufacturing Expansions Signal Industry Growth on East Coast

In a significant move for the pharmaceutical industry, two contract manufacturers have announced major expansions of their biologics manufacturing capabilities on the East Coast of the United States. These developments underscore the growing demand for biologic drugs and highlight the industry's commitment to bolstering domestic production capacity.

NoahAI News6/17/2025

«1...63 64 65...67 »